Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection - Lawitz, Eric; Mangia, Alessandra; Wyles, David; Rodriguez-Torres, Maribel; Hassanein, Tarek; Gordon, Stuart C; Schultz, Michael; Davis, Mitchell N; Kayali, Zeid; Reddy, K. Rajender; Jacobson, Ira M; Kowdley, Kris V; et al. (The New England journal of medicine, 2013)
Keywords: Adult; Aged; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Antiviral drugs; Biological and medical sciences; Chronic infection; Clinical trials; Drug dosages; Drug therapy; Drug Therapy, Combination; Fatigue; Female; General aspects; Genotype; Genotype & phenotype; Genotypes; Headache; Hepacivirus - genetics; Hepatitis; Hepatitis C; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Human viral diseases; Humans; Infectious diseases; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Liver Cirrhosis - virology; Logistic Models; Male; Medical sciences; Middle Aged; Nausea; Neutropenia; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Ribavirin; Ribavirin - adverse effects; Ribavirin - therapeutic use; RNA, Viral - blood; Sofosbuvir; Uridine Monophosphate - adverse effects; Uridine Monophosphate - analogs & derivatives; Uridine Monophosphate - therapeutic use; Viral diseases; Viral hepatitis; Young Adult; United States--US; Infection; Medicine; Digestive diseases; Hepatic disease; Viral disease; Viral hepatitis C